Days af­ter re­port­ing PhI­II fail­ure, GSK pulls BC­MA drug from US mar­ket — but it's not giv­ing up en­tire­ly yet

GSK is pulling its BC­MA-tar­get­ing drug from the US mar­ket, end­ing a short, two-year run for a high-pro­file prod­uct that, among oth­er things, was hailed for mark­ing the phar­ma gi­ant’s re­turn to on­col­o­gy.

The com­pa­ny is ini­ti­at­ing the process for with­draw­al at the re­quest of the FDA, which in turn was based on the neg­a­tive read­out of a con­fir­ma­to­ry Phase III tri­al ear­li­er this month. In that tri­al, GSK’s Blenrep failed to ex­tend pro­gres­sion-free sur­vival over stan­dard of care for pa­tients with mul­ti­ple myelo­ma who have re­ceived at least two pri­or lines of ther­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA